Dynamics in the Costs of Criminality Among Opioid Dependent Individuals

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2014 Oct 6

PMID 25282307

Citations 10

Authors

Emanuel Krebs

Thomas Kerr

Julio Montaner

Evan Wood

Bohdan Nosyk

Affiliations

Soon will be listed here.

Abstract

Background: Research into the avoided crime-related costs associated with methadone maintenance treatment (MMT) is sparse. Our objective was to characterize the dynamics in crime-related costs associated with MMT effectiveness among opioid dependent individuals in Vancouver, Canada.

Methods: We considered individuals enrolled in a prospective study between December, 2011 and May, 2013. Monthly crime-related costs (2013 CAD) were derived from self-reported criminal activity. On the basis of MMT receipt and illicit opioid use, individuals were classified in mutually exclusive health states: (i) MMT high effectiveness; (ii) MMT low effectiveness; (iii) opioid abstinence; or (iv) relapse. We classified individuals as daily, non-daily or non-stimulant users and controlled for demographic and socio-economic characteristics. A two-part multiple regression model was constructed; the first part modeled non-zero cost probability, the second estimated the level of costs. Avoided costs were estimated for each health state and stratified by stimulant use intensity.

Results: Our study included 982 individuals (median age 47, 38% female) for 2232 observations. Individuals on MMT with high effectiveness incurred lower monthly costs of criminality (avoided costs of $6298; 95% C.I. ($1578, $11,017)), as did opioid abstinent individuals ($6563 ($1564, $11,561)). Avoided costs for daily stimulant users were greater than for non-daily users, both for individuals on MMT with high effectiveness ($12,975 vs. $4125) and opioid abstinent ($12,640 vs. $4814).

Conclusion: Using longitudinal data on individuals with a history of MMT, we found substantially lower costs of criminality associated with high effect to MMT. Avoided costs were highest among daily stimulant users that were on MMT with high effectiveness or those opioid abstinent.

Citing Articles

ILC-OPI: impulsive lifestyle counselling versus cognitive behavioral therapy to improve retention of patients with opioid use disorders and externalizing behavior: study protocol for a multicenter, randomized, controlled, superiority trial.

Hesse M, Thylstrup B, Karsberg S, Pedersen M, Pedersen M BMC Psychiatry. 2021; 21(1):183.

PMID: 33827495 PMC: 8028234. DOI: 10.1186/s12888-021-03182-6.

Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia.

Larney S, Jones N, Fiellin D, Nielsen S, Hickman M, Dobbins T Int J Epidemiol. 2020; 49(6):1774-1775.

PMID: 33063106 PMC: 7825957. DOI: 10.1093/ije/dyaa125.

Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting.

Dong H, Hayashi K, Milloy M, DeBeck K, Singer J, Wong H Drug Alcohol Depend. 2020; 212:108005.

PMID: 32370932 PMC: 7462099. DOI: 10.1016/j.drugalcdep.2020.108005.

Unit Costs of Delinquent Acts for Use in Economic Evaluations.

Reckers-Droog V, Goorden M, Dijkgraaf M, Van Eeren H, McCollister K, Roijen L J Ment Health Policy Econ. 2019; 22(2):71-79.

PMID: 31319377 PMC: 6839943.

The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study.

Gisev N, Bharat C, Larney S, Dobbins T, Weatherburn D, Hickman M Lancet Public Health. 2019; 4(7):e334-e342.

PMID: 31201133 PMC: 6673674. DOI: 10.1016/S2468-2667(19)30060-X.

References

Chisholm D, Doran C, Shibuya K, Rehm J . Comparative cost-effectiveness of policy instruments for reducing the global burden of alcohol, tobacco and illicit drug use. Drug Alcohol Rev. 2006; 25(6):553-65. DOI: 10.1080/09595230600944487. View

Nosyk B, Guh D, Bansback N, Oviedo-Joekes E, Brissette S, Marsh D . Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ. 2012; 184(6):E317-28. PMC: 3314060. DOI: 10.1503/cmaj.110669. View

Bovasso G, Cacciola J . The long-term outcomes of drug use by methadone maintenance patients. J Behav Health Serv Res. 2003; 30(3):290-303. DOI: 10.1007/BF02287318. View

French M, McGeary K, Chitwood D, McCoy C, Inciardi J, McBride D . Chronic Drug Use and Crime. Subst Abus. 2002; 21(2):95-109. DOI: 10.1080/08897070009511422. View

Prendergast M, Podus D, Chang E, Urada D . The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies. Drug Alcohol Depend. 2002; 67(1):53-72. DOI: 10.1016/s0376-8716(02)00014-5. View

Zarkin G, Cowell A, Hicks K, Mills M, Belenko S, Dunlap L . Benefits and costs of substance abuse treatment programs for state prison inmates: results from a lifetime simulation model. Health Econ. 2011; 21(6):633-52. PMC: 3165106. DOI: 10.1002/hec.1735. View

Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano D . Longitudinal patterns of drug injection behavior in the ALIVE Study cohort,1988-2000: description and determinants. Am J Epidemiol. 2003; 158(7):695-704. DOI: 10.1093/aje/kwg209. View

Dijkgraaf M, van der Zanden B, de Borgie C, Blanken P, van Ree J, van den Brink W . Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ. 2005; 330(7503):1297. PMC: 558200. DOI: 10.1136/bmj.330.7503.1297. View

Wood E, Stoltz J, Montaner J, Kerr T . Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J. 2006; 3:18. PMC: 1481558. DOI: 10.1186/1477-7517-3-18. View

10.

Wood E, Kerr T, Marshall B, Li K, Zhang R, Hogg R . Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009; 338:b1649. PMC: 2675696. DOI: 10.1136/bmj.b1649. View

11.

Termorshuizen F, Krol A, Prins M, Geskus R, van den Brink W, van Ameijden E . Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend. 2005; 79(2):231-40. DOI: 10.1016/j.drugalcdep.2005.01.013. View

12.

Zarkin G, Dunlap L, Hicks K, Mamo D . Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005; 14(11):1133-50. DOI: 10.1002/hec.999. View

13.

Garrison Jr L, Mansley E, Abbott 3rd T, Bresnahan B, Hay J, Smeeding J . Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health. 2009; 13(1):8-13. DOI: 10.1111/j.1524-4733.2009.00660.x. View

14.

Doran C . Economic evaluation of interventions to treat opiate dependence : a review of the evidence. Pharmacoeconomics. 2008; 26(5):371-93. DOI: 10.2165/00019053-200826050-00003. View

15.

Oliver P, Keen J, Rowse G, Ewins E, Griffiths L, Mathers N . The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care-led methadone maintenance service. Addiction. 2010; 105(4):732-9. DOI: 10.1111/j.1360-0443.2009.02856.x. View

16.

DeBeck K, Shannon K, Wood E, Li K, Montaner J, Kerr T . Income generating activities of people who inject drugs. Drug Alcohol Depend. 2007; 91(1):50-6. PMC: 2047290. DOI: 10.1016/j.drugalcdep.2007.05.003. View

17.

McCollister K, French M, Fang H . The cost of crime to society: new crime-specific estimates for policy and program evaluation. Drug Alcohol Depend. 2010; 108(1-2):98-109. PMC: 2835847. DOI: 10.1016/j.drugalcdep.2009.12.002. View

18.

Schwartz R, Highfield D, Jaffe J, Brady J, Butler C, Rouse C . A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006; 63(1):102-9. DOI: 10.1001/archpsyc.63.1.102. View

19.

Castells X, Kosten T, Capella D, Vidal X, Colom J, Casas M . Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials. Am J Drug Alcohol Abuse. 2010; 35(5):339-49. DOI: 10.1080/00952990903108215. View

20.

Marsch L . The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998; 93(4):515-32. DOI: 10.1046/j.1360-0443.1998.9345157.x. View